RxDoctor Payments Data

Erald Lula

Internal Medicine · Jasper, ALNPI 1790246098

Payments from drug & device makers

$1,438in general payments, 2019–2025

Across 15 payments — averaging $95.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$455
  • AstraZeneca$363
  • Alpha Cognition USA, Inc.$219
  • AbbVie$125
  • Regeneron Healthcare Solutions, Inc.$122
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$74
  • plus $81 from 3 others

What the payments were for

  • Food & beverage$1,438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,438 in reported general payments places this provider in the 65th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$504,842
Medicare patients
466
Services billed
5,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban863$268,003
JanuviaSitagliptin Phosphate204$58,464
XareltoRivaroxaban200$57,969
JardianceEmpagliflozin96$31,358
MyrbetriqMirabegron130$30,582
SantylCollagenase Clostridium Hist.41$18,994
Atorvastatin Calcium947$17,610
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,586
RexultiBrexpiprazole23$12,787
FarxigaDapagliflozin Propanediol43$12,607
Divalproex Sodium253$10,988
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,863
Pantoprazole Sodium551$10,646
LantusInsulin Glargine,hum.Rec.Anlog146$10,581
EntrestoSacubitril/Valsartan29$10,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$363$23,47059 claims
AbbVieCreon, Linzess$125$19,89040 claims
Otsuka America Pharmaceutical, Inc.Rexulti$20$12,78723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Jasper

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →